15. ACQUISITIONS On January 22, 2018, the Company acquired the remaining 73% ownership in Innuvate Health Sciences, LLC ("Innuvate"), which owns a 92% interest in a nutritional product manufacturer. Prior to this acquisition, the Company owned 27% of Innuvate and accounted for it using the equity method. The remaining 8% ownership in the manufacturer will continue to be held by an unrelated third party. Under the terms of the agreement, the Company paid $23.5 million in cash and shares of the Company in exchange for the 73% ownership in Innuvate, subject to adjustment for certain closing items. Innuvate is a contract manufacturer that specializes in softgel and hardshell capsule manufacturing. On February 12, 2018, the Company acquired the remaining 65% ownership in Treviso, LLC ("Treviso"), making Treviso a wholly owned subsidiary of the Company. Treviso is a personal care product manufacturer. Prior to this acquisition, the Company owned 35% of Treviso and accounted for it using the equity method. Under the terms of the purchase agreement, the Company has paid $83.9 million in cash and shares of the Company in exchange for the 65% ownership in Treviso, subject to adjustment for certain closing items. Treviso is a liquid contract manufacturing laboratory for premium personal care products. On February 12, 2018, the Company acquired 100% ownership in L&amp;W Holdings, Inc. ("L&amp;W") making L&amp;W a wholly owned subsidiary of the Company. L&amp;W is a packaging supplier company. Under the terms of the purchase agreement, the Company paid $25.0 million in shares of the Company in exchange for 100% ownership in L&amp;W, subject to adjustment for certain closing items. L&amp;W specializes in the distribution and packaging of products in the cosmetic and nutritional industries. The following table summarizes the fair value of consideration transferred for the acquisitions disclosed above (in thousands): Innuvate Treviso L&amp;W Holdings Total Total cash consideration $ 17,587 $ 14,648 $  $ 32,235 Shares issued in conjunction with acquisition 5,863 69,252 25,000 100,115 Total consideration $ 23,450 $ 83,900 $ 25,000 132,350 Previously held equity interest in equity method Investments (1) 8,748 30,281  39,029 Total $ 32,198 $ 114,181 $ 25,000 $ 171,379 (1) The acquisitions of Innuvate and Treviso are considered step acquisitions, and accordingly, the Company remeasured its pre-existing 27% equity interest in Innuvate and 35% of Treviso immediately prior to completion of the acquisition to its estimated fair value of approximately $39.0 million. As a result of the remeasurement, the Company recorded a gain of approximately $13.6 million within other income (expense), during the first quarter of 2018, representing the excess of the approximate $39.0 million estimated fair value of its pre-existing 27% equity interest in Innuvate and 35% equity interest of Treviso over its transaction date carrying value of approximately $25.4 million. The following table summarizes the fair value of the assets acquired for the acquisitions disclosed above (in thousands): Innuvate Treviso L&amp;W Holdings Life Amount Life Amount Life Amount Total current assets $ 6,219 $ 19,659 $ 7,353 Fixed assets 9,291 33,282 114 Customer list 9 years 5,100 9 years 16,500 7 years 6,500 Order backlog 5 months 200 10 months 4,700 4 months 900 Trademarks 7 years 900 6 years 1,300 5 years 600 Total current liabilities (3,942 ) (3,740 ) (1,495 ) Other non-current liabilities   (1,731 ) Total identifiable net assets acquired 17,768 71,701 12,241 Goodwill 17,230 42,480 12,759 Fair value of noncontrolling interest (2,800 )   Total consideration and value to be allocated to net assets $ 32,198 $ 114,181 $ 25,000 Pro forma and historical results of operations for the acquired companies have not been presented because they are not material, either individually or in the aggregate, to the companys consolidated financial statements.